Doma Biopharmaceutical is a biotech company focused on developing dual-target antibody-drug conjugates (ADCs) for cancer treatment, utilizing proprietary technology to enhance therapeutic efficacy. The company aims to address the need for more effective cancer therapies by advancing its drug candidates through clinical trials and fostering a robust biopharmaceutical ecosystem through project incubation.
Funding
$142.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack the specificity needed to target tumor cells effectively, leading to systemic toxicity and limited efficacy, especially in heterogeneous tumor environments. Traditional antibody-drug conjugates (ADCs) may not adequately address the complexities of tumor biology, resulting in suboptimal therapeutic outcomes.
Solution
Doma Biopharmaceutical is developing dual-target antibody-drug conjugates (ADCs) designed to enhance cancer treatment precision and efficacy. Their approach involves engineering ADCs that simultaneously bind to two distinct targets on cancer cells, increasing target specificity and reducing off-target effects. By targeting multiple pathways, Doma's ADCs aim to overcome drug resistance mechanisms and improve therapeutic outcomes in patients with various types of cancer. These ADCs are designed to deliver a cytotoxic payload directly to tumor cells, minimizing damage to healthy tissues and maximizing the therapeutic window.
Target Audience
Doma Biopharmaceutical's primary target audience includes patients with advanced or metastatic solid tumors who have limited treatment options, as well as oncologists and medical professionals seeking more effective and targeted cancer therapies.
Features
- Dual-targeting mechanism to enhance specificity and reduce off-target toxicity
- Proprietary ADC technology to optimize drug delivery and efficacy
- Focus on developing treatments for cancers with high unmet medical needs
- Pipeline includes DM001 (EGFR/TROP2 dual-targeting ADC) and DM005 (EGFR/c-MET dual-targeting ADC), both in clinical trials
- DM001 is designed to target EGFR and TROP2, two proteins frequently overexpressed in solid tumors
- DM005 is designed to target EGFR and c-MET, two proteins frequently overexpressed in solid tumors